This international symposium was hold in Cádiz in November 2002. In the first conference, a classification of anticancer drugs including all the new compounds was proposed. The role of cholino-kinase in oncogenesis was revised, as well as the possibility to use this model in the development of new drugs. The first group of conferences was finished with a speech about how we are investigating with new drugs, considering the limitations of our traditional paradigm. The second group of conferences included a revision of different drugs: monoclonal antibodies, gefitinib, imatinib and Cox-2 inhibitors. The speakers commented on the results of clinical trials and the future investigation with these drugs. Finally, the third block included a revision a techniques in molecular oncology and a speech about the kind of information that we are achieving through the use of these techniques.
|Translated title of the contribution||10th International course in progress in Oncology: Research and new drugs|
|Number of pages||13|
|Journal||Clinical and Translational Oncology|
|State||Published - Mar 1 2003|
- Monoclonal imatinib
ASJC Scopus subject areas
- Cancer Research